In humans, these biomarkers can only be evaluated in plasma and CSF during life making it difficult to evaluate the influence of alcohol use on AD-related brain pathology during early disease stages. Alternatively, the present preclinical studies utilized the 3xTg-AD mouse model, to evaluate Aβ and Tau pathology in specific brain regions as a translational approach to understand the impact of alcohol drinking on disease progression. By focusing on the NIA-AA Research Framework, the present study has potential to: (a) complement NIA efforts to understand causes of AD; and (b) expand knowledge of alcohol-induced neuropathology in support of NIAAA efforts to understand the impact of alcohol across the lifespan.
